Please indicate the Speaker Program for which you would like to register
  Program Number*: (eg, B123)
*Program number can be found on invitation
  State:

Important Safety Information

Magic is a plasma-derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients. The safety and efficacy of Magic for prophylactic therapy have not been established.

Magic is contraindicated in individuals with a history of life-threatening systemic reactions to C1 esterase inhibitor preparations (including anaphylaxis).

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration of Magic and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Serious arterial and venous thromboembolic events have been reported at recommended doses of C1 Esterase Inhibitor (Human) products, including Magic, following administration to patients with HAE. Risk factors may include having an indwelling venous catheter/access device; prior history of thrombosis; underlying atherosclerosis; use of oral contraceptives or certain androgens; morbid obesity; and immobility. Weigh benefits/risks before administering to patients with known risk factors for TE events and closely monitor such patients during and after Magic administration. TE events also have been reported with C1 Esterase Inhibitor (Human) products when used for unapproved indications at higher than recommended doses.

Patients able to recognize signs and symptoms of HAE attack and comprehend necessary training can self-administer Magic. Patients should not attempt to self-administer unless they have been trained and determined to be capable by healthcare provider. Advise patients to seek medical attention immediately following self-administration for laryngeal attacks, and to seek medical attention if progress of any attack makes them unable to properly prepare or administer dose of Magic.

Magic is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most serious adverse reaction reported in subjects who received Magic in clinical studies was an increase in the severity of pain associated with HAE. Dysgeusia was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.

Magic has not been evaluated in pregnant women or nursing mothers, and should be used only if clearly needed. The safety and efficacy of Magic have not been established in children (ages 0 through 12) or in the geriatric population. In clinical trials, the half-life of Magic was shorter and clearance was faster in children than in adults; the clinical implication is not known.

For questions regarding a Speaker Program or registration,
please contact solutions@trifusionsolutions.com or 212-673-7140.